🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interesting... 🤔

🫁 The VA continues to lead the most successful lung screening program ever implemented in the US. These data confirm it’s saving lives as demonstrated in the yellow line representing unprecedented declines in stage IV cases. #ATS2025 VA Research House Committee on Veterans' Affairs Veterans Affairs

The 'Omega' valve and a new thought process in the management of reflux. Amazing to hear from our chairman and thought leader about Reflux! ninh nguyen The American Foregut Society UC Irvine Surgery #reflux #foregut #gerd

Preserving funding for cancer research is a nonpartisan issue. Lend your voice to the fight to restore #lungcancerresearch funding. #lcsm Link in thread.

Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. ja.ma/43beXGr

I see the physician shortage as the greatest opportunity for physicians to take back medicine and lead healthcare delivery into a new golden age.

Won't be at ASCO this year, but I'm excited to see/hear about the studies and read the Twitter debates!!! Sandip Patel MD FASCO Narjust Florez, MD, FASCO Misako Nagasaka Drew Moghanaki Brendon Stiles Stephen V Liu, MD Linda Martin Patrick Forde Jonathan Spicer MD PhD #asco2025

Hari B. Keshava Sandip Patel MD FASCO Narjust Florez, MD, FASCO Misako Nagasaka Drew Moghanaki Brendon Stiles Stephen V Liu, MD Linda Martin Patrick Forde I recommend checking out the CM816 OS, the outcomes by molecular profile from 77T, the first report of NeoADAURA findings and the complete data on arms 1, 2 and 4 of NeoCOAST2! Lots of great data that will inform practice and the next generation of phase 3 trials!

Congratulations to all those elected to the IASLC Board! It was such an amazing slate of candidates this year! #LCSM

Don’t forget to visit us at booth #14031 at #ASCO2025!

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Presented at #ASCO25: In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN trial

Hamada et al. hypothesized that adding radiotherapy to neoadjuvant chemotherapy would improve local control, thus improving survival outcomes. The additional treatment did have a higher MPR rate, but did not necessarily translate to improved PFS or OS. 🔗 Read more:

#ASCO25 update on CheckMate 77T: Periop nivo vs plb in resectable NSCLC (mFUP 41 mo) M.Provencio 🔹 EFS: 46.6 vs 16.9 mo (HR 0.61), 30-mo 61% vs 43% 🔹 Benefit regardless of KRAS, STK11, KEAP1, PD-L1 status 🔹 ctDNA/pCR linked to EFS 🔹 OS NR trend HR 0.85 (30mo 78% vs 72%)

So you've heard the practice changing exercise CHALLENGE trial! But what did that groundbreaking exercise program actually look like day-to-day? Let's explore the "Structured Exercise Program" based on info from their paper supplement on NEJM #ASCO2025 #ASCO25 1/10

This is an awesome trial and reinforces the importance of exercise for our patients with cancer!! #exercise #cancer

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

OS data is out!!

Dr. Megan Daly presents at #ASCO25 the SWOG Cancer Research Network S1914 Phase 3 study. Unfortunately, SBRT + atezolizumab failed to improve PFS or OS over SBRT in early stage unresectable/inoperable high-risk NSCLC. ⭐️Stopped early for futility ⭐️PFS 1.85, OS 1.76 for SBRT+atezo ⭐️⬆️local POD

Just amazing and game changing for our patients with lung cancer!!